Moderation of antidepressant response by the serotonin transporter gene

No abstract is available for this paper.

• Publication year

  2009

• Venue

  British Journal of Psychiatry

• Publication date

  2009-07-01

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1192/bjp.bp.108.062521PMID 19567893
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Differential efficacy of escitalopram and nortriptyline on dimensional measures of depression

  2009cited by this paper
• SLC6A4 variation and citalopram response

  2009cited by this paper
• Adverse reactions to antidepressants.

  2009cited by this paper
• The moderation by the serotonin transporter gene of environmental adversity in the aetiology of mental illness: review and methodological analysis

  2008cited by this paper
• Serotonin transporter gene influences the time course of improvement of "core" depressive and somatic anxiety symptoms during treatment with SSRIs for recurrent mood disorders.

  2007cited by this paper
• Interactive effects of sex and 5-HTTLPR on mood and impulsivity during tryptophan depletion in healthy people.

  2007cited by this paper
• Measuring depression: comparison and integration of three scales in the GENDEP study

  2007cited by this paper
• Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample.

  2007cited by this paper
• PLINK: a tool set for whole-genome association and population-based linkage analyses.

  2007cited by this paper
• Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression.

  2007cited by this paper
• Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients

  2007cited by this paper
• Mapping regulatory variants for the serotonin transporter gene based on allelic expression imbalance

  2007cited by this paper
• Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice.

  2006cited by this paper
• Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression.

  2006cited by this paper
• Development of depression: sex and the interaction between environment and a promoter polymorphism of the serotonin transporter gene.

  2006cited by this paper
• Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder.

  2006cited by this paper
• Estrogen selectively increases tryptophan hydroxylase-2 mRNA expression in distinct subregions of rat midbrain raphe nucleus: association between gene expression and anxiety behavior in the open field.

  2006cited by this paper
• Estimation and testing of genotype and haplotype effects in case‐control studies: comparison of weighted regression and multiple imputation procedures

  2006cited by this paper
• Simultaneous genotyping of four functional loci of human SLC6A4, with a reappraisal of 5-HTTLPR and rs25531

  2006cited by this paper
• Sex-specific genetic architecture of whole blood serotonin levels.

  2005cited by this paper
• Efficiency and power in genetic association studies

  2005cited by this paper
• Rational inferences about departures from Hardy-Weinberg equilibrium.

  2005cited by this paper
• Haploview: analysis and visualization of LD and haplotype maps

  2005cited by this paper
• An expanded evaluation of the relationship of four alleles to the level of response to alcohol and the alcoholism risk.

  2005cited by this paper
• Transcription factor AP-2 and monoaminergic functions in the central nervous system

  2005cited by this paper
• Estrogen augmentation of antidepressants in perimenopausal depression: a pilot study.

  2005cited by this paper
• Organization of the human serotonin transporter gene

  2005cited by this paper
• Sequence analysis of the serotonin transporter and associations with antidepressant response.

  2005cited by this paper
• Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression.

  2004cited by this paper
• DNA from Buccal Swabs Recruited by Mail: Evaluation of Storage Effects on Long-Term Stability and Suitability for Multiplex Polymerase Chain Reaction Genotyping

  2003cited by this paper
• Age-dependent antidepressant pharmacogenomics: polymorphisms of the serotonin transporter and G protein beta3 subunit as predictors of response to fluoxetine and nortriptyline.

  2003cited by this paper
• Ovarian steroid regulation of serotonin reuptake transporter (SERT) binding, distribution, and function in female macaques*

  2003cited by this paper
• A comparison of bayesian methods for haplotype reconstruction from population genotype data.

  2003cited by this paper
• Physical and Functional Interactions among AP-2 Transcription Factors, p300/CREB-binding Protein, and CITED2*

  2003cited by this paper
• Inference of population structure using multilocus genotype data: linked loci and correlated allele frequencies.

  2003cited by this paper
• Age-related decline of serotonin transporters in living human brain of healthy males.

  2002cited by this paper
• Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.

  2001cited by this paper
• A new statistical method for haplotype reconstruction from population data.

  2001cited by this paper
• Serotonin 5-HT1A Receptor Binding Potential Declines with Age as Measured by [11C]WAY-100635 and PET

  2001cited by this paper
• Synergistic activation of the serotonin-1A receptor by nuclear factor-kappa B and estrogen.

  2001cited by this paper
• Synergistic Activation of the Serotonin-1A Receptor by Nuclear Factor-κB and Estrogen

  2001cited by this paper
• Factors affecting fluvoxamine antidepressant activity: influence of pindolol and 5-HTTLPR in delusional and nondelusional depression.

  2001cited by this paper
• Remission rates during treatment with venlafaxine or selective serotonin reuptake inhibitors

  2001cited by this paper
• Age-related decline in central serotonin transporter availability with [(123)I]beta-CIT SPECT.

  2000cited by this paper
• Age-related decline in central serotonin transporter availability with [123I]β-CIT SPECT

  2000cited by this paper
• Diagnosis and Clinical Measurement in Psychiatry: A Reference Manual for SCAN

  1999cited by this paper
• Population studies of polymorphisms of the serotonin transporter protein gene.

  1999cited by this paper
• A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo.

  1999cited by this paper
• Genomic Control for Association Studies

  1999cited by this paper
• Familial concordance of fluvoxamine response as a tool for differentiating mood disorder pedigrees.

  1998cited by this paper
• Polymorphism within the promoter of the serotonin transporter gene and antidepressant efficacy of fluvoxamine

  1998cited by this paper
• Estradiol-17 beta increases serotonin transporter (SERT) mRNA levels and the density of SERT-binding sites in female rat brain.

  1997cited by this paper
• The density of 5-hydoxytryptamine2A receptors in forebrain is increased at pro-oestrus in intact female rats.

  1997cited by this paper
• Onset of antidepressant activity: Reexamining the structure of depression and multiple actions of drugs

  1996cited by this paper
• The UKU side effect rating scale: A new comprehensive rating scale for psychotropic drugs and a cross‐sectional study of side effects in neuroleptic‐treated patients

  1987cited by this paper
• Modulation by estradiol of serotonin receptors in brain

  1982cited by this paper
• A New Depression Scale Designed to be Sensitive to Change

  1979cited by this paper
• Cell-mediated immunity to encephalitogenic factor (MMI test) in women with cervical dysplasia and carcinoma in situ: the effects of serum.

  1978cited by this paper
• INSTITUTE OF PSYCHIATRY

  1969cited by this paper
• Development of a rating scale for primary depressive illness.

  1967cited by this paper
• An inventory for measuring depression.

  1961cited by this paper
• A RATING SCALE FOR DEPRESSION

  1960cited by this paper

• Polymorphic variants of SLC6A4 and TPH1 genes as predictors of sertraline efficacy and safety in patients with mixed anxiety-depressive disorder: a pilot study

  2025cites this paper
• Molecular pathways linking the serotonin transporters (SERT) to depressive disorder: from mechanisms to treatments.

  2025cites this paper
• Pharmacogenetics in Child and Adolescent Psychiatry: Background and Evidence-Based Clinical Applications

  2024cites this paper
• The Impact of Development on Antidepressant and Placebo Response in Anxiety Disorders: A Bayesian Hierarchical Meta-Analytic Examination of Randomized Controlled Trials in Children, Adolescents, and Adults

  2024cites this paper
• Serotonin transporter 5-HTTLPR polymorphism and escitalopram treatment response in patients with major depressive disorder

  2024cites this paper
• The Role of Pharmacogenetics in Personalizing the Antidepressant and Anxiolytic Therapy

  2023cites this paper
• Pharmacogenetics of selective serotonin reuptake inhibitors (SSRI): A serotonin reuptake transporter (SERT)-based approach.

  2023cites this paper
• Biomarkers as predictors of treatment response to tricyclic antidepressants in major depressive disorder: A systematic review.

  2022cites this paper
• Early life stress and the role of environmental and molecular moderators in the ontology of pathological and resilient behavioral phenotypes

  2022cites this paper
• Treatment resistant depression

  2021cites this paper
• Pharmacogenetically Guided Escitalopram Treatment for Pediatric Anxiety Disorders: Protocol for a Double-Blind Randomized Trial

  2021cites this paper
• Pharmacogenetic‐based management of depression: Role of traditional Persian medicine

  2021cites this paper
• Pharmacogenetic/Pharmacogenomic Tests for Treatment Prediction in Depression.

  2021cites this paper
• Serotonergic receptor gene polymorphism and response to selective serotonin reuptake inhibitors in ethnic Malay patients with first episode of major depressive disorder

  2021cites this paper
• Treatment-Resistant Depression Revisited: A Glimmer of Hope

  2021cites this paper
• Pharmacogenomics: an Update for Child and Adolescent Psychiatry

  2020cites this paper
• Pharmacogenetic association of bi- and triallelic polymorphisms of SLC6A4 with antidepressant response in major depressive disorder.

  2020cites this paper
• An integrative analysis of 5HTT-mediated mechanism of hyperactivity to non-threatening voices

  2020cites this paper
• Biomarker-Based Treatment Selection: A Precision Medicine Approach for Depression

  2019cites this paper
• Affective Disorders and Gender Differences

  2019cites this paper
• Antidepressants

  2019cites this paper
• Affective Disorders and Gender Differences

  2019cites this paper
• The involvement of sleep in the relationship between the serotonin transporter gene-linked polymorphic region (5-HTTLPR) and depression: A systematic review.

  2019cites this paper
• Genotype, phenotype, and medication recommendation agreement among commercial pharmacogenetic-based decision support tools

  2018cites this paper
• Impulsive Internet Game Play Is Associated With Increased Functional Connectivity Between the Default Mode and Salience Networks in Depressed Patients With Short Allele of Serotonin Transporter Gene

  2018cites this paper
• Insights and barriers to clinical use of serotonin transporter pharmacogenetics in antidepressant therapy.

  2018cites this paper
• The serotonin transporter and the activity regulated cytoskeleton‐associated protein genes in antidepressant response and resistance: 5‐HTTLPR and other variants

  2018influential citation
• Progress in Elucidating Biomarkers of Antidepressant Pharmacological Treatment Response: A Systematic Review and Meta-analysis of the Last 15 Years

  2017cites this paper
• Suicide attempt in mental disorders (MeDi): Association with 5-HTT, IL-10 and TNF-alpha polymorphisms.

  2017cites this paper
• Striatal N-Acetylaspartate Synthetase Shati/Nat8l Regulates Depression-Like Behaviors via mGluR3-Mediated Serotonergic Suppression in Mice

  2017cites this paper
• Reiterate and integrate the adverse effect of antipsychotic agent and its attenuation by Ginkgo Biloba Extract on reproductive system and functions of rodents

  2017cites this paper
• Association of 5-HTTLPR Polymorphism with the Nursing Diagnoses and the Achievement of Nursing Outcomes in Patients with Major Depression

  2017cites this paper
• Serotonin Transporter Gene Polymorphisms and Selective Serotonin Reuptake Inhibitor Tolerability: Review of Pharmacogenetic Evidence

  2017cites this paper
• Delineation of molecular pathway activities of the chronic antidepressant treatment response suggests important roles for glutamatergic and ubiquitin–proteasome systems

  2017cites this paper
• Personalized Therapeutics: First Take Home Messages

  2017cites this paper
• Genetic Moderators of the Impact of Physical Activity on Depressive Symptoms.

  2016cites this paper
• Association Between The 5-HTTLPR Polymorphism and Response to Citalopram in Turkish Patients With Major Depressive Disorder

  2016cites this paper
• Impact of 5-HTTLPR on SSRI serotonin transporter blockade during emotion regulation: A preliminary fMRI study.

  2016cites this paper
• 5-HTTLPR and gender differences in affective disorders: A systematic review.

  2016cites this paper
• Pharmacogenetic studies: a tool to improve antidepressant therapy

  2016cites this paper
• Drug-symptom networking: Linking drug-likeness screening to drug discovery.

  2016cites this paper
• Serotonin transporter (5-HTTLPR) and norepinephrine transporter (NET) gene polymorphisms: susceptibility and treatment response of electroconvulsive therapy in treatment resistant depression.

  2015cites this paper
• Targeting drug sensitivity predictors: New potential strategies to improve pharmacotherapy of human brain disorders.

  2015cites this paper
• Genetic Variations in the Serotonergic System Mediate a Combined, Weakened Response to SSRI Treatment: A Proposed Model,

  2015cites this paper
• Serotonin pathway polymorphisms and the treatment of major depressive disorder and anxiety disorders.

  2015cites this paper
• NEUROPROTECTIVE EFFECTS OF GINGER AGAINST SERTRALINE AS ANTIDEPRESSANT DRUG-INDUCED LESIONS IN SPINAL CORD OF MICE -

  2015cites this paper
• Serotonin gene polymorphisms and lifetime mood disorders in predicting interferon-induced depression in chronic hepatitis C.

  2015cites this paper
• Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life

  2015cites this paper
• Association of serotonin transporter (SLC6A4) & receptor (5HTR1A, 5HTR2A) polymorphisms with response to treatment with escitalopram in patients with major depressive disorder: A preliminary study

  2015cites this paper
• The impact of 5-HTTLPR on acute serotonin transporter blockade by escitalopram on emotion processing: Preliminary findings from a randomised, crossover fMRI study

  2014influential citation
• Genetic predictors of antidepressant side effects: A grouped candidate gene approach in the Genome-Based Therapeutic Drugs for Depression (GENDEP) study

  2014cites this paper
• Pharmacogenetics of Antidepressant Drugs: An Update

  2014cites this paper
• Influence of RGS2 on Sertraline Treatment for Social Anxiety Disorder

  2014cites this paper
• The Influence of 5-HTTLPR Genotype on the Association between the Plasma Concentration and Therapeutic Effect of Paroxetine in Patients with Major Depressive Disorder

  2014cites this paper
• Escitalopram Efficacy in Depression: A Cross-Ethnicity Examination of the Serotonin Transporter Promoter Polymorphism

  2014cites this paper
• Are there meaningful biomarkers of treatment response for depression?

  2014cites this paper
• Understanding the pharmacogenetics of selective serotonin reuptake inhibitors

  2014cites this paper
• A Neurobiological Hypothesis of Treatment-Resistant Depression – Mechanisms for Selective Serotonin Reuptake Inhibitor Non-Efficacy

  2014cites this paper
• Menopausal status could modulate the association between 5-HTTLPR and antidepressant efficacy in depressed women: a pilot study

  2014cites this paper
• A Preliminary Examination of the Relationship Between the 5-HTTLPR and Childhood Emotional Abuse on Depressive Symptoms in 10-12-Year-Old Youth.

  2014cites this paper
• Drugs, genes and the blues: pharmacogenetics of the antidepressant response from mouse to man.

  2014cites this paper
• From Pharmacogenetics to Pharmacogenomics: The Way toward the Personalization of Antidepressant Treatment

  2014cites this paper
• The development and application of a polymerase chain reaction (PCR) based assay to determine the impact of genetic variation in South African patients diagnosed with depression

  2014cites this paper
• World Journal of Pharmaceutical Sciences

  2014cites this paper
• The development and application of a polymerase chain reaction (PCR) based assay to determine the impact of genetic variation in South African patients diagnosed with depression

  2014cites this paper
• Allelic diversity of selected human neurotransmitter genes in South African ethnic groups

  2014cites this paper
• From the Intersection of Pharmacology, Imaging, and Genetics to the Advancement of Personalized Medicine

  2014cites this paper
• Genome-Based Therapeutic Drugs for Depression ( GENDEP ) study Genetic predictors of antidepressant side effects : A grouped candidate gene approach in the

  2014cites this paper
• Interaction between specific forms of childhood maltreatment and the serotonin transporter gene (5-HTT) in recurrent depressive disorder.

  2013cites this paper
• Pharmacogenetics in major depression: a comprehensive meta-analysis.

  2013cites this paper
• Serotonin transporter gene (5-HTTLPR) polymorphism and efficacy of selective serotonin reuptake inhibitors--do we have sufficient evidence for clinical practice.

  2013cites this paper
• Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression

  2013cites this paper
• Clinical validity of cytochrome P450 metabolism and serotonin gene variants in psychiatric pharmacotherapy

  2013cites this paper
• Toward a neuroimaging treatment selection biomarker for major depressive disorder.

  2013cites this paper
• 2 Genes of rationality Building blocks for the neurobiology of reasoning

  2013cites this paper
• Psychobiological model of personality and psychopharmacotherapy outcomes in treatment of depression and schizophrenia.

  2013cites this paper
• Systematic review and meta-analysis of serotonin transporter genotype and discontinuation from antidepressant treatment

  2013cites this paper
• Allele‐specific expression of the serotonin transporter and its transcription factors following lamotrigine treatment in vitro

  2013cites this paper
• Personalized medicine in psychiatry: problems and promises

  2013cites this paper
• Pharmacogenetics of antidepressant drugs: An update after almost 20 years of research

  2013cites this paper
• Biology, Genes, and Resilience

  2013cites this paper
• AVPR1A and SLC6A4 Polymorphisms in Choral Singers and Non-Musicians: A Gene Association Study

  2012influential citation
• Association of the 5-HTT gene-linked promoter region (5-HTTLPR) polymorphism with psychiatric disorders: review of psychopathology and pharmacotherapy

  2012cites this paper
• Serotonin and decision making processes.

  2012cites this paper
• Whole-hemisphere autoradiography of 5-HT₁B receptor densities in postmortem alcoholic brains.

  2012cites this paper
• Pharmacogenetically Driven Treatments for Alcoholism

  2012cites this paper
• Pharmacogenetics of antidepressants and mood stabilizers.

  2012cites this paper
• Altered response to the selective serotonin reuptake inhibitor escitalopram in mice heterozygous for the serotonin transporter: an electrophysiological and neurochemical study.

  2012cites this paper
• The genetics of selective serotonin reuptake inhibitors.

  2012influential citation
• Pharmacogenetics of antidepressant drugs: current clinical practice and future directions.

  2012cites this paper
• Pharmacogenetics in Psychiatry

  2012cites this paper
• Association between Serotonin Transporter-Linked Polymorphic Region and Escitalopram Antidepressant Treatment Response in Korean Patients with Major Depressive Disorder

  2012cites this paper
• Genes, Economics, and Happiness.

  2012cites this paper
• CEP Discussion Paper No 1127 February 2012 Genes , Economics , and Happiness

  2012cites this paper
• Stressful life events and the serotonin transporter gene (5-HTT) in recurrent clinical depression.

  2012cites this paper
• Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with antidepressant efficacy.

  2012influential citation
• Should pharmacogenetics be incorporated in major depression treatment? Economic evaluation in high- and middle-income European countries.

  2012cites this paper
• Major depressive disorder: new clinical, neurobiological, and treatment perspectives.

  2012cites this paper
• Developmental Influence of the Serotonin Transporter on the Expression of Npas4 and GABAergic Markers: Modulation by Antidepressant Treatment

  2012cites this paper
• Citalopram versus other anti-depressive agents for depression.

  2012cites this paper